Integra LifeSciences Holdings (Nasdaq: IART) reported earnings on April 25. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Integra LifeSciences Holdings beat slightly on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded and GAAP earnings per share contracted significantly.

Margins dropped across the board.

Revenue details
Integra LifeSciences Holdings booked revenue of $196.2 million. The 11 analysts polled by S&P Capital IQ predicted a top line of $192.7 million on the same basis. GAAP reported sales were 8.4% higher than the prior-year quarter's $181.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Non-GAAP EPS came in at $0.71. The 14 earnings estimates compiled by S&P Capital IQ averaged $0.60 per share on the same basis. GAAP EPS of $0.23 for Q1 were 39% lower than the prior-year quarter's $0.38 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 61.9%, 300 basis points worse than the prior-year quarter. Operating margin was 8.9%, 600 basis points worse than the prior-year quarter. Net margin was 3.4%, 290 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $205.4 million. On the bottom line, the average EPS estimate is $0.70.

Next year's average estimate for revenue is $827.2 million. The average EPS estimate is $2.98.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 158 members out of 169 rating the stock outperform, and 11 members rating it underperform. Among 55 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 54 give Integra LifeSciences Holdings a green thumbs-up, and one gives it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is outperform, with an average price target of $38.23.

Over the decades, small-cap stocks, like Integra LifeSciences Holdings have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.